Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 12 approved new animal drug applications (NADA's) from Merial Ltd. to Phoenix Scientific, Inc.

DATES:

This rule is effective July 26, 2000.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Thomas J. McKay, Center for Veterinary Medicine (HFV-102), Food and Drug Start Printed Page 45877Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0213.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Merial Ltd., 2100 Ronson Rd., Iselin, NJ 08830-3077, has informed FDA that it has transferred ownership of, and all rights and interests in, the following approved NADA's to Phoenix Scientific, Inc., 3915 South 48th St. Terrace, PO Box 6457, St. Joseph, MO 64506-0457:

NADA No.Product Name
033-157SPECTAM® (spectinomycin) Scour Halt
040-040SPECTAM® (spectinomycin) Injection
045-416BUTATRONTM (phenylbutazone) Injection
048-287Oxytetracycline-50 (oxytetracycline) Injection
055-002TEVOCIN (chloramphenicol) Injection
093-483SPECTAM® (spectinomycin) Injectable
119-142PVL Iron Dextran Injectable
123-815Dexamethasone Sodium Phosphate Injection
124-241PVL Oxytocin Injection
128-089ZONOMETH (dexamethasone) Sterile Solution
200-147GENTA-JECT® (gentamicin sulfate) Injection
200-153NEO 200 (neomycin sulfate) Oral Solution

Accordingly, the agency is amending the regulations in parts 520 and 522 (21 CFR parts 520 and 522) in §§ 520.1485, 520.2122, 522.390, 522.540, 522.1044, 522.1183, 522.1662a, 522.1680, and 522.2120 to reflect the transfer of ownership. An entry for Phoenix Scientific, Inc., already exists in § 522.1720 Phenylbutazone Injection following the approval of a supplemental ANADA 200-126 (61 FR 54332, October 18, 1996).

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects in 21 CFR Parts 520 and 522

  • Animal drugs
End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and 522 are amended as follows:

End Amendment Part Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for 21 CFR part 520 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

2. Section 520.1485 Neomycin sulfate oral solution is amended in paragraph (b) by removing “050604”.

End Amendment Part
[Amended]
Start Amendment Part

3. Section 520.2122 Spectinomycin dihydrochloride oral solution is amended in paragraph (b)(1) by removing “050604” and adding in its place “059130”.

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

4. The authority citation for 21 CFR part 522 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

5. Section 522.390 Chloramphenicol injection is amended in paragraph (b) by removing “050604” and adding in its place “059130”.

End Amendment Part
[Amended]
Start Amendment Part

6. Section 522.540 Dexamethasone injection is amended in paragraphs (d)(2)(i) and (e)(2) by removing “050604” and adding in its place “059130”.

End Amendment Part
[Amended]
Start Amendment Part

7. Section 522.1044 Gentamicin sulfate injection is amended in paragraph (b)(4) by removing “050604” and adding in its place “059130”.

End Amendment Part
[Amended]
Start Amendment Part

8. Section 522.1183 Iron hydrogenated dextran injection is amended in paragraph (e)(1) by removing “050604” and adding in its place “059130”.

End Amendment Part
[Amended]
Start Amendment Part

9. Section 522.1662a Oxytetracycline hydrochloride injection is amended in paragraph (i)(2) by removing “050604” and adding in its place “059130”.

End Amendment Part
[Amended]
Start Amendment Part

10. Section 522.1680 Oxytocin injection is amended in paragraph (b) by removing “050604” and adding in its place “059130”.

End Amendment Part
[Amended]
Start Amendment Part

11. Section 522.2120 Spectinomycin dihydrochloride injection is amended in paragraph (b) by removing “050604” and adding in its place “059130”.

End Amendment Part Start Signature

Dated: July 18, 2000.

Claire M. Lathers,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 00-18828 Filed 7-25-00; 8:45 am]

BILLING CODE4160-01-F